DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Elsahy-Waters syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleElsahy-Waters syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for elsahy-waters syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Elsahy-Waters syndrome is a rare multiple congenital anomalies and intellectual disability syndrome. A 2010 report described a 44-year-old woman and her 45-year-old brother, born to consanguineous parents, who showed striking resemblance to earlier described patients. The condition is characterised by moderate mental retardation, hypospadias, and craniofacial features including brachycephaly, facial asymmetry, exotropia, hypertelorism, broad nose, concave nasal ridge, underdeveloped midface, prognathism, and radicular dentin dysplasia. The report of an affected woman and her brother from consanguineous parents supported autosomal recessive inheritance. All previously reported patients had been male.
Two abstracts discuss aquaporin-1 (AQP1), a water channel found in many tissues. A 2022 review noted that aquaporins facilitate osmotically driven water flux and sometimes movement of small molecules, and that targeting aquaporin interactomes may offer new therapeutic avenues because targeting individual aquaporins remains challenging. A 2016 study identified three novel human AQP1 blockers by virtual screening that inhibited water flux in Xenopus laevis oocyte swelling assays at low micromolar concentrations. These compounds bound at the extracellular entrance of the channel, and mutagenesis showed lysine 36, not conserved among the aquaporin family, was involved in binding.
No abstract links Elsahy-Waters syndrome to aquaporin-1 or any other drug target. No abstract reports any treatment, clinical trial, or survival data for the syndrome. What is missing is any molecular or genetic basis for Elsahy-Waters syndrome beyond the inheritance pattern, any patient-derived cell or animal model, any funding for drug screening, and any trial design that could test a candidate compound in this ultra-rare condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Molecular Sciences · 2022 · 22 citations · open access
Insight into the Mammalian Aquaporin Interactome
AbstractAquaporins (AQPs) are a family of transmembrane water channels expressed in all living organisms. AQPs facilitate osmotically driven water flux across biological membranes and, in some cases, the movement of small molecules (such as glycerol, urea, CO2, NH3, H2O2). Protein–protein interactions play essential roles in protein regulation and function. This review provides a comprehensive overview of the current knowledge of the AQP interactomes and addresses the molecular basis and functional significance of these protein–protein interactions in health and diseases. Targeting AQP interactomes may offer new therapeutic avenues as targeting individual AQPs remains challenging despite intense efforts.
American Journal of Medical Genetics Part A · 2010 · 14 citations
Elsahy–Waters syndrome: Evidence for autosomal recessive inheritance
AbstractElsahy-Waters or branchioskeletogenital syndrome is a rare MCA/MR syndrome characterized by moderate mental retardation, hypospadias and characteristic craniofacial morphology, which includes brachycephaly, facial asymmetry, exotropia, hypertelorism/telechantus, broad nose, concave nasal ridge, underdeveloped midface, prognathism, and radicular dentin dysplasia. Here we report on a 44-year-old woman and her 45-year-old brother, born to consanguineous parents, who show a striking resemblance to the earlier described patients. The hitherto reported patients were male and in one pedigree parents were consanguineous. The present report of an affected woman and her brother, born to consanguineous parents, supports autosomal recessive inheritance of this condition. We provide a short review of all previously reported patients with Elsahy-Waters syndrome and related entities.
AbstractHuman aquaporin-1 (hAQP1) is a water channel found in\nmany tissues\nand potentially involved in several human pathologies. Selective inhibitors\nof hAQP1 are discussed as novel treatment opportunities for glaucoma,\nbrain edema, inflammatory pain, and certain types of cancer. However,\nonly very few potent and chemically attractive blockers have been\nreported to date. In this study we present three novel hAQP1 blockers\nthat have been identified by virtual screening and inhibit water flux\nthrough hAQP1 in <i>Xenopus laevis</i> oocyte swelling assays\nat low micromolar concentrations. The newly discovered compounds display\nno chemical similarity to hitherto known hAQP1 blockers and bind at\nthe extracellular entrance of the channel, close to the ar/R selectivity\nfilter. Futhermore, mutagenesis studies showed that Lys36, which is\nnot conserved among the hAQP family, is crucially involved in binding\nand renders the discovered compounds suitable as leads for the development\nof selective hAQP1 inhibitors.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
